摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[2-(methoxy(methyl)carbamoyl)phenyl]carbamic acid tert-butyl ester | 249765-58-0

中文名称
——
中文别名
——
英文名称
[2-(methoxy(methyl)carbamoyl)phenyl]carbamic acid tert-butyl ester
英文别名
tert-butyl N-{2-[methoxy(methyl)carbamoyl]phenyl}carbamate;tert-butyl N-[2-[methoxy(methyl)carbamoyl]phenyl]carbamate
[2-(methoxy(methyl)carbamoyl)phenyl]carbamic acid tert-butyl ester化学式
CAS
249765-58-0
化学式
C14H20N2O4
mdl
——
分子量
280.324
InChiKey
WFMAXGNIZVRSKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    387.0±25.0 °C(Predicted)
  • 密度:
    1.167±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    67.9
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of Carbazoles and Carbazole-Containing Heterocycles via Rhodium-Catalyzed Tandem Carbonylative Benzannulations
    作者:Wangze Song、Xiaoxun Li、Ka Yang、Xian-liang Zhao、Daniel A. Glazier、Bao-min Xi、Weiping Tang
    DOI:10.1021/acs.joc.6b00212
    日期:2016.4.1
    tri-, tetra-, and pentacyclic heterocycles from different types of aryl propargylic alcohols. These tandem reactions provide efficient access to highly substituted carbazoles, furocarbazoles, pyrrolocarbazoles, thiophenocarbazoles, and indolocarbazoles. While tricyclic heterocycles could be derived from vinyl aryl propargylic alcohols, tetra- and pentacyclic heterocycles were synthesized from diaryl
    多环芳族化合物是药物和其他材料的重要成分。我们已经开发了一系列Rh催化的串联羰基苯环用于从不同类型的芳基炔丙醇合成三环,四环和五环杂环。这些串联反应提供了高效取代高度取代的咔唑,呋喃咔唑,吡咯并咔唑,噻吩并咔唑和吲哚并咔唑的途径。虽然三环杂环可以衍生自乙烯基芳基炔丙醇,但四环和五环杂环是由二芳基炔丙醇合成的。串联羰基苯环化反应是由π-酸性铑(I)催化剂介导的向炔烃的亲核加成生成的,从而生成关键的金属-卡宾中间体,然后被一氧化碳捕获,形成乙烯酮,用于6π电环化。总体而言,在所有这些串联的羰基苯并环化反应中均形成三个键和两个环。
  • DIHYDROQUINAZOLINONE ANALOGUES
    申请人:SMETHURST Christian
    公开号:US20140296230A1
    公开(公告)日:2014-10-02
    The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 4 and A 1 to A 5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    本发明涵盖了一般式(I)的化合物,其中基团R1至R4和基团A1至A5具有声明和说明中所给出的含义。该发明的化合物适用于治疗由细胞过度或异常增殖所特征的疾病,包括含有这些化合物的药物制剂以及它们作为药物的用途。
  • [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
    申请人:MERCK & CO INC
    公开号:WO2001016121A1
    公开(公告)日:2001-03-08
    In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. At a ring position adjacent to a ring nitrogen atom, the heterocyclic ring has at least one substituent which includes a moiety, linked to the heterocyclic ring via an alkylene moiety, an alkynylene moiety or an azo group. Invention compounds are capable of a wide variety of uses including modulating physiological processes by functioning as agonists and antagonists of receptors in the nervous system, as insecticides, and as fungicides. The invention further provides methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds including the novel compounds referred to above. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of the above-described heterocyclic compounds.
    根据本发明,提供了一类新型的杂环化合物及其使用方法。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环,其中至少包含一个氮原子和至少一个碳原子。在靠近环氮原子的环位置上,杂环环有至少一个取代基,包括一个官能团,通过烷基官能团、炔基官能团或偶氮基团连接到杂环环上。发明的化合物能够广泛应用,包括通过作为神经系统受体的激动剂和拮抗剂来调节生理过程,作为杀虫剂和杀菌剂。本发明还提供了使用特定定义的杂环化合物类来调节兴奋性氨基酸受体活性的方法,包括上述新型化合物。在一种实施例中,提供了调节代谢性谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。本发明还揭示了预防与肺系统疾病、神经系统疾病、心血管系统疾病、胃肠系统疾病、内分泌系统疾病、外分泌系统疾病、皮肤疾病、癌症和眼科系统疾病相关的疾病状态的方法。本发明还揭示了上述杂环化合物的药物可接受的盐形式。
  • Dihydroquinazolinone analogues
    申请人:Smethurst Christian
    公开号:US09199988B2
    公开(公告)日:2015-12-01
    The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    本发明涵盖通式(I)的化合物,其中R1到R4和A1到A5的基团具有声明和说明书中给出的含义。该发明的化合物适用于治疗以过度或异常细胞增殖为特征的疾病,包括含有这些化合物的制药制剂以及它们作为药物的用途。
  • Rhodium-Catalyzed Tandem Annulation and (5 + 1) Cycloaddition: 3-Hydroxy-1,4-enyne as the 5-Carbon Component
    作者:Xiaoxun Li、Wangze Song、Weiping Tang
    DOI:10.1021/ja408829y
    日期:2013.11.13
    A Rh-catalyzed tandem annulation and (5 + 1) cycloaddition was realized. 3-Hydroxy-1,4-enyne served as the new 5-carbon component for the (5 + 1) cycloaddition. Substituted carbazoles, dibenzofurans, and tricyclic compounds containing a cyclohexadienone moiety could be prepared efficiently. The identification of a byproduct suggests that metal carbene and ketene intermediates may be involved in the (5 + 1) cycloaddition.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐